002603.SZ
Strong BuyUnloved QualityShijiazhuang Yiling Pharmaceutical Co., Ltd. · Healthcare · China · $3.8B
CNY 15.35 +2.2% · close 30 Sep · scored 3 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.
Read
Shijiazhuang Yiling Pharmaceutical is a leading Chinese pharmaceutical company specializing in patented Traditional Chinese Medicines (TCM). The company's flagship respiratory product, Lianhua Qingwen, holds a dominant market share in China's anti-viral and cold medicine segments. Its competitive moat is built on proprietary academic research and a robust pipeline of cardiovascular and oncology TCMs.
FINANCIAL SUMMARY (CNY)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.5B | 10.3B | 6.5B | 7.8B | -14.5% | 7.9B | 8.5B | 9.0B | 7.5% |
| EPS (CNY) | 1.41 | 0.81 | -0.43 | 0.77 | -18.3% | 0.82 | 0.97 | 1.15 | 22.1% |
| Shares | 1.7B | 1.7B | 1.7B | 1.7B | 0.0% | 1.7B | — | — | — |
| Debt | 871.4M | 1.4B | 26.5M | 25.7M | -69.1% | 22.3M | — | — | — |
| Equity | 10.9B | 11.4B | 10.2B | 11.0B | 0.2% | — | — | — | — |
| Op CF | 3.5B | 155.5M | 611.0M | 1.8B | -20.1% | 2.1B | — | — | — |
| Inv CF | -2.0B | -899.2M | 1.6B | -1.0B | — | — | — | — | — |
| Fin CF | -637.0M | -220.6M | -2.3B | -513.6M | — | — | — | — | — |
Calmer than 66% of stocks we rank over the past year (33% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 002603.SZ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 002603.SZ | Shijiazhuang Yiling Pharmaceutical Co., Ltd.(you) | $3.8B | 92 | Strong Buy |
| 000513.SZ | Livzon Pharmaceutical Group Inc. | $3.6B | 90 | Strong Buy |
| 2096.HK | Simcere Pharmaceutical Group Limited | $3.7B | 96 | Strong Buy |
| 000423.SZ | Dong-E-E-Jiao Co., Ltd. | $4.3B | 95 | Strong Buy |
| 600566.SS | Hubei Jumpcan Pharmaceutical Co., Ltd. | $3.4B | 96 | Strong Buy |
| 600535.SS | Tasly Pharmaceutical Group Co., Ltd | $3.0B | 96 | Strong Buy |
| 600380.SS | Joincare Pharmaceutical Group Industry Co.,Ltd. | $2.5B | 91 | Strong Buy |
| 000999.SZ | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. | $5.8B | 92 | Strong Buy |
| 600750.SS | China Resources Jiangzhong Pharmaceutical Co.,Ltd | $2.1B | 92 | Strong Buy |
| 600062.SS | China Resources Double-Crane Pharmaceutical Co.,Ltd. | $2.5B | 87 | Strong Buy |
Peer medians: ROE 4.3% · P/E 27.8x · Gross margin 52.7%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.